1
|
Choo CW, Ahn YS, Kim KH, Lee JH, Moon KY, Choi BC, Kang YJ, Kim HY, Sim CH, Han JE, Kim CH, Jang EJ, Lee Y, Moon JW, Park DS, Won HJ, Kim AN, Kim JY, Kim KR, Ahn JH, Lee JY, Gwak H, Kim JH. Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (Follitrope™) in Inducing Controlled Ovarian Stimulation in Infertile Women in Real-World Practice: a Prospective Cohort Study. Reprod Sci 2023; 30:2842-2852. [PMID: 37067727 PMCID: PMC10480279 DOI: 10.1007/s43032-023-01228-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 03/27/2023] [Indexed: 04/18/2023]
Abstract
To evaluate the safety and effectiveness of recombinant human follicle-stimulating hormone (rhFSH [Follitrope™]) in infertile women undergoing in vitro fertilization (IVF). To identify predictors of ovarian response that induce optimal clinical outcomes. This multicenter prospective study enrolled infertile women who were scheduled to undergo IVF after ovarian stimulation with rhFSH (Follitrope™) following the gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist protocol. Predictive factors for ovarian response were identified in the GnRH antagonist group based on the number of oocytes retrieved. A total of 516 infertile women were enrolled, among whom 136 (except one who withdrew before administration) received rhFSH using the GnRH agonist protocol and 379 using the antagonist protocol. The mean number of oocytes retrieved was 13.4 in the GnRH agonist group and 13.6 in the GnRH antagonist group. The clinical pregnancy rates were 32.3% (30/93) and 39.9% (115/288) in the GnRH agonist and antagonist groups, respectively. The incidence of ovarian hyperstimulation syndrome was 1.8% and 3.4% in the GnRH agonist and antagonist groups, respectively. No other significant safety risks associated with rhFSH administration were identified. Body mass index, basal serum FSH and anti-Müllerian hormone levels, and antral follicle count were identified as predictors of ovarian response by multiple regression with backward elimination, and the final regression model accounted for 26.5% of the response variability. In real-world practice, rhFSH (Follitrope™) is safe and effective in inducing ovarian stimulation in infertile women. Patient characteristics identified as predictors can be considered to be highly related to optimal clinical outcomes.
Collapse
Affiliation(s)
- Chang-Woo Choo
- Department of Gynecologic Endocrinology, Female Infertility, Fertility Preservation, Seoul Maria Fertility Hospital, Seoul, Republic of Korea
| | | | - Kyu Hyun Kim
- Bucheon Maria Fertility Hospital, Bucheon, Republic of Korea
| | - Jae Ho Lee
- Ilsan Maria Fertility Hospital, Goyang, Republic of Korea
| | | | - Bum-Chae Choi
- Center for Infertility & Recurrent Miscarriage, Creation & Love Women's Hospital, Gwangju, Republic of Korea
| | - Young Je Kang
- Pyeongchon Maria Fertility Hospital, Anyang, Republic of Korea
| | - Hye Young Kim
- Department of Obstetrics and Gynecology, Fertility Center, Agaon Fertility Clinic, Seoul, Republic of Korea
| | - Chae Hee Sim
- Mamapapa and Baby Ob/Gy Clinic, Ulsan, Republic of Korea
| | - Ji Eun Han
- Miraeyeon Fertility Clinic, Seoul, Republic of Korea
| | | | - Eun Jeong Jang
- Pyeongchon Maria Fertility Hospital, Anyang, Republic of Korea
| | - Yoojin Lee
- MizMedi Hospital, Seoul, Republic of Korea
| | | | - Dong Soo Park
- CHA Daegu Medical Center, CHA University School of Medicine, Daegu, Republic of Korea
| | | | - An Na Kim
- Pyeongchon Maria Fertility Hospital, Anyang, Republic of Korea
| | - Ju-Young Kim
- Sae Ran Women's Clinic, Jeonju, Republic of Korea
| | | | - Ji Hyun Ahn
- Department of Obstetrics and Gynecology, Fertility Center, Agaon Fertility Clinic, Seoul, Republic of Korea
| | | | - Heemin Gwak
- Life Sciences, LG Chem, Ltd., Seoul, Republic of Korea
| | - Ji Hyang Kim
- Department of Obstetrics and Gynecology, Fertility Center of CHA Bundang Medical Center, CHA University School of Medicine, 64 Yatap-ro, Bundang-gu, Seongnam, Gyeonggi-do, 13520, Republic of Korea.
| |
Collapse
|
2
|
Kim JG, Kim KI, Park KB, Park YG, Bae JH, Seo YJ, Seon JK, Shon OJ, Ahn JH, Wang L, Wang JH, Choi ES, Ha JK, Han HS, Moon SW. Safety and effectiveness of intra-articular injection of a highly cross-linked hyaluronic acid, LBSA0103 (Synovian): Results from a post-marketing surveillance study in South Korea. PLoS One 2023; 18:e0287222. [PMID: 37347765 PMCID: PMC10287010 DOI: 10.1371/journal.pone.0287222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Accepted: 06/01/2023] [Indexed: 06/24/2023] Open
Abstract
This study aimed to assess the safety and effectiveness of the highly cross-linked hyaluronic acid-LBSA0103-in patients with knee osteoarthritis (OA) as per the prescribing information (PI) in South Korea. A total of 3,140 subjects aged ≥19 years were enrolled in this post-marketing surveillance (PMS) study from 2013 to 2019. The subjects received one or two injections of LBSA0103. The median duration of follow-up was 308 days. Adverse events (AEs), adverse drug reactions (ADRs), and serious AEs (SAEs) were monitored. Effectiveness was evaluated based on an index of effectiveness in accordance with the guidelines established by the Ministry of Food and Drug Safety and using a 100-mm visual analog scale (VAS) for weight-bearing pain. Overall, 250 subjects (7.96%) experienced 292 AEs and of these, unexpected AEs occurred in 114 subjects (3.63% [95% CI: 3.00-4.35]). Injection site pain was the most frequent AE reported by 81 subjects (2.58% [95% confidence intervals (CI): 2.05-3.20]). One hundred subjects experienced 108 ADRs (3.18% [95% CI: 2.60, 3.86]) and 15 unexpected ADRs were experienced by 13 subjects (0.41% [95% CI: 0.22-0.71]). Seventeen subjects experienced 22 SAEs (0.54% [95% CI: 0.32-0.87]) during the entire PMS period, and all were considered "unlikely" related to the study drug. Most AEs were mild in terms of severity and resolved during the study period. LBSA0103 was also effective in relieving symptomatic pain in knee OA patients. The condition in more than 80% of the subjects was considered to be improved when assessed by the investigators. LBSA0103 resulted in a significant reduction in the mean VAS score at 12 weeks after the first and second injections (24.79 (± 20.55) mm and 17.63 (±12.31) mm, respectively; p<0.0001). In conclusion, LBSA0103, used for the treatment of knee OA in a real-world setting, was well tolerated, with an acceptable safety profile and consistent therapeutic effect.
Collapse
Affiliation(s)
- Jae Gyoon Kim
- Department of Orthopedic Surgery, Korea University College of Medicine Ansan Hospital, Gyeongki-do, Republic of Korea
| | - Kang-Il Kim
- Department of Orthopedic Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - Ki-Bong Park
- Department of Orthopedic Surgery, Good Samsun Hospital, Busan, Republic of Korea
| | - Yong-Geun Park
- Department of Orthopedic Surgery, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Republic of Korea
| | - Ji Hoon Bae
- Department of Orthopedic Surgery, Korea University College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
| | - Young-Jin Seo
- Department of Orthopedic Surgery, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea
| | - Jong-Keun Seon
- Department of Orthopedic Surgery, Chonnam National University Hwasun Hospital and Medical School, Jeonnam, Republic of Korea
| | - Oog Jin Shon
- Department of Orthopedic Surgery, School of Medicine, Yeungnam University Hospital, Daegu, Republic of Korea
| | - Ji Hyun Ahn
- Department of Orthopedic Surgery, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea
| | - Lih Wang
- Department of Orthopedic Surgery, Dong-A University College of Medicine, Dong-A University Hospital, Busan, Korea
| | - Joon-Ho Wang
- Department of Orthopedic Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Eui Sung Choi
- Department of Orthopedic Surgery, Chungbuk National University College of Medicine, Cheongju, Korea
| | - Jeong-Ku Ha
- Department of Orthopedic Surgery, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea
| | - Hyuk-Soo Han
- Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Sang Won Moon
- Department of Orthopedic Surgery, Inje University Haeundae Paik Hospital, Busan, Korea
| |
Collapse
|
3
|
Blicharski T, Łukasik P, Plebanski R, Żęgota Z, Szuścik M, Moster E, Pavelka K, Jeon S, Park SL. Efficacy and Safety of Intra-Articular Cross-Linked Sodium Hyaluronate for the Treatment of Knee Osteoarthritis: A Prospective, Active-Controlled, Randomized, Parallel-Group, Double-Blind, Multicenter Study. J Clin Med 2023; 12:jcm12082982. [PMID: 37109318 PMCID: PMC10145240 DOI: 10.3390/jcm12082982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/12/2023] [Accepted: 04/17/2023] [Indexed: 04/29/2023] Open
Abstract
The safety and efficacy of Hyruan ONE (test product), an intra-articular cross-linked sodium hyaluronate injection, to treat mild-to-moderate knee osteoarthritis was compared with that of Durolane (comparator) in a prospective, active-controlled, parallel-group, double-blind (masked-observed), multicenter non-inferiority study. European patients (n = 284) were randomized 1:1 (test product:comparator) and received one injection of cross-linked hyaluronic acid (60 mg/3 mL). In total, 280 patients completed the study. The primary endpoint of mean change in Western Ontario and McMaster University (WOMAC)-Likert Pain sub-scores from baseline at week 13 revealed changes of -5.59 and -5.54 for the test and comparator groups, respectively, demonstrating non-inferiority of the test product (difference, -0.05 [95% confidence interval, -0.838 to 0.729]). Secondary endpoint results, which included changes in WOMAC-Likert Pain sub-score from baseline to 26 weeks post-injection and changes in WOMAC-Likert Total score and Physical Function and Stiffness sub-scores, changes in patients' and investigators' global assessments, use of rescue medication, and responder rates at 13 and 26 weeks post-injection were similar between the groups. Incidence of adverse events was also similar. In both groups, most treatment-emergent adverse events were mild/moderate. Hyruan ONE was non-inferior to the comparator at 13 weeks post-injection in European patients with mild-to-moderate knee osteoarthritis.
Collapse
Grants
- T.B., T.H., A.G., J.B., P.Ł., R.P., Z.Ż., M.S., E.M., K.P., and T.T. received a study grant from LG Chem, Ltd. S.J. and S.L.P. are full-time employees of LG Chem, Ltd LG Chem
Collapse
Affiliation(s)
- Tomasz Blicharski
- Clinic of Rehabilitation and Orthopedics, Medical University of Lublin, 20-090 Lublin, Poland
| | - Piotr Łukasik
- Trauma and Orthopedic Ward, NZOZ Medi-Spatz, 44-100 Gliwice, Poland
| | | | - Zbigniew Żęgota
- Specjalistyczny Osrodek Leczniczo Badawczy (Specialist Treatment and Research Center), 14-100 Ostroda, Poland
| | - Marek Szuścik
- Orthopedic Department, Rydygier's Hospital, 31-826 Krakow, Poland
| | - Erik Moster
- Rheumatic Center of Dr. Mostera, 61500 Brno, Czech Republic
| | - Karel Pavelka
- Institute of Rheumatology, 12850 Prague, Czech Republic
| | - Seonhui Jeon
- Life Sciences, LG Chem, Ltd., Seoul 07336, Republic of Korea
| | - So La Park
- Life Sciences, LG Chem, Ltd., Seoul 07336, Republic of Korea
| |
Collapse
|
4
|
Lee KJ, Ryu JK, Cho YH, Shin WY, Kim JS, Yoon YW, Jang JY, Kim WH, Beom JW, Kang SM. Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan ® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study. Drug Des Devel Ther 2023; 17:1047-1062. [PMID: 37051292 PMCID: PMC10084874 DOI: 10.2147/dddt.s391288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 02/23/2023] [Indexed: 04/14/2023] Open
Abstract
Purpose This study aimed to assess the effectiveness and safety of a fixed-dose combination of rosuvastatin and valsartan (Rovatitan®) in Korean patients with concomitant hypertension and hyperlipidemia. Patients and Methods A total of 1008 eligible patients with concomitant hypertension and hyperlipidemia were enrolled and treated for 12 weeks. Both upward and downward drug dose titrations were allowed based on the investigator's discretion. This study evaluated the effectiveness of the study drug, defined by the percentage of patients achieving the blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) treatment targets. Additionally, regression analyses were conducted to evaluate the factors associated with the effectiveness and safety of the study drug. Of the 1008 patients enrolled in the study, 911 were analyzed for clinical effectiveness. Results At 12 weeks, 84.6% and 75.9% of patients treated with the study drug achieved their BP and LDL-C targets, respectively, and 64.8% of patients achieved both targets simultaneously. Furthermore, the percentage of patients who achieved their BP and LDL-C treatment targets demonstrated a trend across the respective risk groups; the higher the risk group, the lower the success of attaining the respective target. This trend was also observed regardless of the prior antihypertensive and/or lipid-lowering treatments. According to regression analysis, poor metabolic profiles, including a higher body mass index (BMI) and higher BP and LDL-C levels at baseline, were significantly associated with treatment failure for BP. Among the 1005 patients included in the safety analysis, 17 patients (1.7%) experienced serious adverse events; however, none were considered related to the study drug. Conclusion The study drug used for the treatment of concomitant hypertension and hyperlipidemia in a real-world setting was effective and was well tolerated. Therefore, the study drug is suggested as a good alternative to increase patient convenience and compliance, particularly in those taking multiple medications.
Collapse
Affiliation(s)
- Kwang Je Lee
- Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea
| | - Jae-Kean Ryu
- Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea
| | | | - Won Yong Shin
- Department of Cardiology, Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea
| | - Jeong Su Kim
- Cardiovascular Center, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Young Won Yoon
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Ji Yong Jang
- Department of Cardiology, National Health Insurance Service Ilsan Hospital, Ilsan, Korea
| | - Won Ho Kim
- Eulji University School of Medicine, Daejeon, Korea
| | - Jong Wook Beom
- Department of Cardiology, Jeju National University Hospital, Jeju, Korea
| | - Seok-Min Kang
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
- Correspondence: Seok-Min Kang, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Tel +82 2-2647-3225, Email
| | | |
Collapse
|
5
|
Park JY, Ko JH, Lee HJ, Park JH, Lee J, Sa S, Shin EJ, Lee BY. Up-Scale Synthesis of p-(CH 2=CH)C 6H 4CH 2CH 2CH 2Cl and p-ClC 6H 4SiR 3 by CuCN-Catalyzed Coupling Reactions of Grignard Reagents with Organic Halides. ACS Omega 2022; 7:46849-46858. [PMID: 36570214 PMCID: PMC9773938 DOI: 10.1021/acsomega.2c05951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 12/01/2022] [Indexed: 06/17/2023]
Abstract
Grignard reagents featuring carbanion characteristics are mostly unreactive toward alkyl halides and require a catalyst for the coupling reaction. With the need to prepare p-(CH2=CH)C6H4CH2CH2CH2Cl on a large scale, the coupling reaction of p-(CH2=CH)C6H4MgCl with BrCH2CH2CH2Cl was attempted to screen the catalysts, and CuCN was determined to be the best catalyst affording the desired compound in 80% yield with no formation of Wurtz coupling side product CH2=CHC6H4-C6H4CH=CH2. The p-(CH2=CH)C6H4Cu(CN)MgCl species was proposed as an intermediate based on the X-ray structure of PhCu(CN)Mg(THF)4Cl. p-ClC6H4MgCl did not react with sterically encumbered R3SiCl (R = n-Bu or n-octyl). However, the reaction took place with the addition of 3 mol % CuCN catalyst, affording the desired compound p-ClC6H4SiR3. The structures of p-(CH2=CH)C6H4CH2CH2CH2MgCl and p-ClC6H4MgCl were also elucidated, which existed as an aggregate with MgCl2, suggesting that some portion of the Grignard reagents were possibly lost in the coupling reaction due to coprecipitation with the byproduct MgCl2. R3SiCl (R = n-Bu or n-octyl) was also prepared easily and economically with no formation of R4Si when SiCl4 was reacted with 4 equiv of RMgCl. Using the developed syntheses, [p-(CH2=CH)C6H4CH2CH2CH2]2Zn and iPrN[P(C6H4-p-SiR3)2]2, which are potentially useful compounds for the production of PS-block-PO-block-PS and 1-octene, respectively, were efficiently synthesized with substantial cost reductions.
Collapse
Affiliation(s)
- Ju Yong Park
- Department
of Molecular Science and Technology, Ajou
University, Suwon16499, South Korea
| | - Ji Hyeong Ko
- Department
of Molecular Science and Technology, Ajou
University, Suwon16499, South Korea
| | - Hyun Ju Lee
- Department
of Molecular Science and Technology, Ajou
University, Suwon16499, South Korea
| | - Jun Hyeong Park
- Department
of Molecular Science and Technology, Ajou
University, Suwon16499, South Korea
| | - Junseong Lee
- Department
of Chemistry, Chonnam National University, Gwangju61186, South Korea
| | | | | | - Bun Yeoul Lee
- Department
of Molecular Science and Technology, Ajou
University, Suwon16499, South Korea
| |
Collapse
|